Clinical Trial Update: Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating erenumab for fibromyalgia has been withdrawn, ending development for this indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia

Drugs mentioned

• AIMOVIG (ERENUMAB-AOOE)

Snippet

Sponsor: United States Naval Medical Center, Portsmouth | Conditions: Fibromyalgia | Phase 3 | Status: WITHDRAWN